Establishment and characterization of four human epithelial ovarian carcinoma cell linesHIRTE, H. W; KAISER, J. S; BACCHETTI, S et al.Cancer. 1994, Vol 74, Num 3, pp 900-906, issn 0008-543XArticle

Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targetsHIRTE, H. W; CLARK, D. A.Cellular immunology (Print). 1991, Vol 136, Num 1, pp 122-132, issn 0008-8749Article

Telomerase activity associated with acquisition of malignancy in human colorectal cancerCHADENEAU, C; HAY, K; HIRTE, H. W et al.Cancer research (Baltimore). 1995, Vol 55, Num 12, pp 2533-2536, issn 0008-5472Article

Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumourCLARK, D. A; HIRTE, H. W; BUICK, R. N et al.British journal of cancer. 1988, Vol 58, Num 4, pp 415-418, issn 0007-0920, 4 p.Article

A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinomaHIRTE, H. W; CLARK, D. A; MAZURKA, J et al.Gynecologic oncology (Print). 1992, Vol 44, Num 3, pp 223-226, issn 0090-8258Article

Reversal of suppression of lymphokine-activated killer cells by transforming growth-factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibodyHIRTE, H. W; CLARK, D. A; O'CONNELL, G et al.Cellular immunology (Print). 1992, Vol 142, Num 1, pp 207-216, issn 0008-8749Article

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancersMACKENZIE, M. J; HIRTE, H. W; SIU, L. L et al.Annals of oncology. 2004, Vol 15, Num 4, pp 665-670, issn 0923-7534, 6 p.Article

Telomerase activity in human ovarian carcinomaCOUNTER, C. M; HIRTE, H. W; BACCHETTI, S et al.Proceedings of the National Academy of Sciences of the United States of America. 1994, Vol 91, Num 8, pp 2900-2904, issn 0027-8424Article

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)SAHEBJAM, S; BEDARD, P. L; KAMEL-REID, S et al.British journal of cancer. 2013, Vol 109, Num 4, pp 943-949, issn 0007-0920, 7 p.Article

Malignant Ascites Fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesisRICHARDSON, M; GUNAWAN, J; HATTON, M. W. C et al.Gynecologic oncology (Print). 2002, Vol 86, Num 3, pp 279-287, issn 0090-8258Article

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-α versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinomaHIRTE, H. W; MILLER, D; TONKIN, K et al.Gynecologic oncology (Print). 1997, Vol 64, Num 1, pp 80-87, issn 0090-8258Article

Transient global amnesia associated with acute heparin-induced thrombocytopeniaWARKENTIN, T. E; HIRTE, H. W; ANDERSON, D. R et al.The American journal of medicine. 1994, Vol 97, Num 5, pp 489-491, issn 0002-9343Article

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumoursRAZAK, Ara; HOTTE, S. J; ZHU, J et al.British journal of cancer. 2011, Vol 104, Num 5, pp 756-762, issn 0007-0920, 7 p.Article

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers : a Princess Margaret Hospital Phase II Consortium studyHOTTE, S. J; OZA, A; WINQUIST, E. W et al.Annals of oncology. 2006, Vol 17, Num 2, pp 334-340, issn 0923-7534, 7 p.Article

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsMOORE, M; HIRTE, H. W; SIU, L et al.Annals of oncology. 2005, Vol 16, Num 10, pp 1688-1694, issn 0923-7534, 7 p.Article